(Reuters) – Pfizer announced on Monday to acquire the Metsera weight loss developer for $ 7.3 billion (6.22 billion euros) on Monday (6.22 billion euros), a transaction that must consolidate its position on the lucrative market for obesity.
The American obesity medication segment has been booming for a few years, carried by the success of very effective treatments by Novo Nordisk and Eli Lilly.
Pfizer will pay 47.50 dollars per cash share, which represents a bonus of approximately 43% compared to the last closing course of the New York company Metsera.
Metsera could also receive additional $ 22.50 per share if certain performance objectives are achieved. Its title jumped 56% in the trade-off on Monday.
Metsera, founded in 2022, develops injectable and oral drugs to treat obesity.
Its main candidate, the Met-097i, showed an average weight loss of 11.3% in patients during an intermediate phase trial, the company said at the start of the year.
The operation is Pfizer’s last attempt to set up on the obesity medication market, after several failures in the development of its own weight loss drugs.
The Financial Times, citing sources, reported discussions between Pfizer and Metsera on Sunday.
(Written by Mrinmay Dey in Bangalore; Coralie Lamarque and Etienne Breban; edited by Augustin Turpin)
Copyright © 2025 Thomson Reuters
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
